Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) England and Wales Not Appli ...

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Ralph Torbay - Head, Commercial David Berman - Head, R&D Brian Di Donato - CFO Mohammed Dar - CMO Conference Call Participants Michael Yee - Jefferies Jessica Fye - JP Morgan Tyler Van Buren - TD Cowen Eric Schmidt - Cantor Fitzgerald Paul Jeng - Guggenheim Avantika Joshi - Mizuho Peter Lawson - Barclays Charlie Moore - Baird Jeet Mukherjee ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ________ to ________ Commission File Number 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) England and Wales Not Applicable (State o ...

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements | | | Three Months Ended | | Nine Months Ended | | | --- | --- | --- | --- | --- | --- | | | | September 30, | | September 30, | | | | | 2023 | 2022 | 2023 | 2022 | | | Notes | £'000 | £'000 | £'000 | £'000 | | Product revenue, net | 3 | 49,719 | 33,252 | 137,285 | 64,926 | | Pre-product revenue, net | 3 | — | 3,05 ...

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Clayton Robertson - Head of IR Bahija Jallal - CEO and Director Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head of Commercial David Berman - Head of R&D Mohammed Dar - CMO Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Justin Zelin - BTIG Graig Suvannavejh - Mizuho Justin Kim - Oppenheimer Michael Schmidt - Guggenheim Patrick Trucchio - H.C. W ...

Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements | | Notes | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | At January 1, 2022 | | 88 | 212,238 | 89 | 54,357 | 386,167 | (481,392) | 171,547 | | Loss for the period | | — | — | — | — | — | (16,128) | (16,128) | | Other comprehensive | | | | | | | | | | income | | — | — | 205 | — | — | — | 205 | | Total comprehensive | | | | | | | | | | loss for ...

▸ CM: all received prior anti-PD1 and anti-CTLA4 IMC-F106C was well tolerated Most frequent related AE was Grade 1/2 CRS, consistent with proposed mechanism | --- | --- | --- | --- | |----------------------------------------------|--------------------------------|-----------------------|------------| | Preferred Term (MedDRA v23.1) | 0.3 – 10 mcg † N=18 | 20 – 320 mcg † N=37 | Total N=55 | | All grades events in ≥ 25% of patients , n % | | | | | At least one event | 18 (100) | 34 (92) | 52 (95) | | Pyrexia* ...

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - Chief Executive Officer & Director Ralph Torbay - Head of Commercial Brian Di Donato - Chief Financial Officer & Head of Strategy David Berman - Head of Research & Development Conference Call Participants Michael Yee - Jefferies Patrick Trucchio - H.C. Wainwright Justin Kim - Oppenheimer Justin Zelin - BTIG Peter Lawson - Barclays ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...